Involvement of ubiquitination in the decrease of intestinal P-glycoprotein in a streptozotocin-induced diabetic mouse...

Area of Science:

• Pharmacology and Toxicology
• Molecular Biology
• Diabetic Complications

Background:

• P-glycoprotein (P-gp) is an efflux pump affecting drug pharmacokinetics.
• Decreased intestinal P-gp expression is observed in type 1 diabetes.
• Nitric oxide synthase (NOS) activation is implicated, but other mechanisms are unknown.

Purpose of the Study:

• To investigate the involvement of the ubiquitin-proteasome system in reduced intestinal P-gp expression in diabetes.
• To elucidate the detailed molecular mechanisms beyond NOS activation.

Main Methods:

• Utilized a streptozotocin (STZ)-induced type 1 diabetic mice model.
• Assessed ileal P-gp ubiquitination levels and protein expression.
• Evaluated 26S proteasome activity.
• Administered an NO donor to diabetic mice.

Main Results:

• STZ-induced diabetes significantly increased ileal P-gp ubiquitination.
• Intestinal P-gp protein levels decreased in diabetic mice.
• NO donor treatment enhanced intestinal ubiquitinated P-gp levels.
• 26S proteasome activity remained unchanged, indicating specific up-regulation of ubiquitination.

Conclusions:

• The ubiquitin-proteasome system, specifically enhanced ubiquitination, contributes to decreased intestinal P-gp expression in diabetes.
• Nitric oxide (NO) accelerates this process, linking NOS activation to P-gp downregulation via the ubiquitin-proteasome pathway.
• Findings reveal a novel mechanism impacting the pharmacokinetics of P-gp substrate drugs in diabetic patients.